Personalized mRNA vaccine lowers melanoma risk
Merck and Moderna’s experimental mRNA vaccine cut the risk melanoma returned by 42%, opening a door for a new way to treat cancer. CNN’s Meg Tirrell reports.
Merck and Moderna’s experimental mRNA vaccine cut the risk melanoma returned by 42%, opening a door for a new way to treat cancer. CNN’s Meg Tirrell reports.
